BSV163/DOPE-mediated TRAIL Gene Transfection Acts Synergistically with Chemotherapy Against Cisplatin-Resistant Ovarian Cancer.

Ovarian cancer is the seventh most frequently diagnosed cancer among women worldwide. Most patients experience recurrence and succumb eventually to resistant disease, underscoring the need for an alternative treatment option. In the presented manuscript, we investigated the effect of the TRAIL-gene, transfected by an innovative bioinspired lipid vector BSV163/DOPE in the presence or absence of cisplatin, to fight against sensitive and resistant ovarian cancer. We showed that BSV163/DOPE can transfect ovarian cancer cell lines (Caov3, OVCAR3, and our new cisplatin-resistant, CR-Caov3) safely and efficiently. In addition, TRAIL-gene transfection in association with cisplatin inhibited cellular growth more efficiently (nearly 50% in Caov3 cells after the combined treatment, and 15% or 25% by each treatment alone, respectively) owing to an increase in apoptosis rate, caspases activity and TRAIL's death receptors expression. Most importantly, such synergistic effect was also observed in CR-Caov3 cells demonstrated by an apoptosis rate of 35% following the combined treatment in comparison with 17% after TRAIL-gene transfection or 6% after cisplatin exposition. These results suggest this combination may have potential application for sensitive as well as refractory ovarian cancer patients. Ovarian cancer is the most lethal gynecologic cancer with recurrent or resistant disease observed in 70% of patients. We described herein the anti-cancer effect of a novel lipid vector BSV163/DOPE-mediated TRAIL gene transfection in association with cisplatin in-sensitive and-resistant ovarian cancer cells. The combined treatment successfully enhanced cisplatin cytotoxicity and helped to overcome cisplatin resistance in CR-Caov3 cells.image